Almirall, S.a.

This study looked at the long-term safety and effectiveness of lebrikizumab for adults and teenagers with moderate-to-severe atopic dermatitis (eczema). Participants who completed a previous year-long study were given lebrikizumab for up to 2 more years. The goal was to see how m…

This study tested a skin ointment called tirbanibulin on adults with actinic keratosis, a common sun-related skin condition that can turn into skin cancer. The goal was to see if the ointment works safely on larger areas of the face or scalp, up to 100 square centimeters. About 2…

This observational study followed 331 adults with moderate to severe plaque psoriasis who were treated with tildrakizumab (Ilumetri®) in routine clinical practice. Researchers measured skin clearance (using PASI scores) and quality of life over up to 2 years. The goal was to see …

This study involved 291 adults with mild-to-moderate scalp psoriasis who used a prescription cream (CAL/BDP PAD cream). Researchers measured how satisfied patients were with the treatment, its effect on their quality of life, and how well it worked in everyday use. The goal was t…

This early-stage study tested the safety of a new drug called LAD191 in 69 adults—some healthy and some with an autoimmune disease. Researchers gave single or multiple doses to see how the body handles the drug and whether it causes side effects. The goal was not to treat the dis…

This early-stage study tested the safety and tolerability of a new drug called LAD603 in 92 healthy adults aged 18 to 65. Participants received either the drug or a placebo to see how the body processes it and whether it causes side effects. The goal was not to treat any disease,…